Combination chemotherapy with cisplatin

Chemotherapy is one way of mesothelioma treatments that have been shown to improve survival in randomized and controlled trials. The study, published in 2003 by Vogelzang and colleagues compared cisplatin alone with combination chemotherapy of cisplatin and pemetrexed (brand name Alimta) chemotherapy) in patients not receiving chemotherapy for malignant pleural mesothelioma previously and are not candidates for more aggressive "curative" operation. This experiment is the first reported survival benefit of chemotherapy in malignant pleural mesothelioma, showed statistically significant improvement in average survival of 10 months in patients treated with cisplatin alone to 13.3 months in the combination group of patients receiving pemetrexed supplementation with folate and vitamin B12.

Vitamin supplements given to most patients in the trial and related side-effects of pemetrexed was significantly smaller in patients who received pemetrexed when they also receive a daily folate 500mcg oral and intramuscular vitamin B12 1000mcg every 9 weeks compared with patients receiving pemetrexed without vitamin supplementation. Objective response rate increased from 20% in the cisplatin group to 46% in the combination of pemetrexed. Some side effects such as nausea and vomiting, stomatitis, and diarrhea are more common in the combination of pemetrexed group but only affects a minority of patients and the overall combination of pemetrexed and cisplatin was well tolerated when patients received vitamin supplements, good quality of life and pulmonary function tests improved in the combination of pemetrexed. In February 2004, the United States Food and Drug Administration approved pemetrexed for the treatment of malignant pleural mesothelioma. However, there are still unanswered questions about the optimal use of chemotherapy, including when to start treatment, and the optimal number of cycles to give.

Cisplatin in combination with raltitrexed has demonstrated an improvement in survival similar to that reported for pemetrexed in combination with cisplatin, but raltitrexed is no longer available commercially for this indication. For patients unable to tolerate pemetrexed, cisplatin in combination with gemcitabine or vinorelbine is an alternative, or vinorelbine alone, although survival benefit has not been shown for this drug. For patients who can not be used cisplatin, carboplatin can be substituted but non-random data that have shown lower response rates and high levels of haematological toxicity for carboplatin-based combinations, although the survival rates similar to patients receiving cisplatin.

In January 2009, the U.S. FDA approved the use of conventional therapies like surgery and in combination with radiation or chemotherapy in stage I or II Mesothelioma after research conducted by a national study by Duke University concluded an increase of nearly 50 points at the level of remission.

Xtreme Fat Loss Diet System!

Mesothelioma Chemotherapy, Cisplatin and Carboplatin

A mesothelioma article recently published in scientific journals Lung Cancer that examined the benefits and costs with a combination of Cisplatin and Carboplatin and Pemetrexed Pemetrexed for mesothelioma chemotherapy.

PA Photo Asbestos Exposure Mesothelioma Chemotherapy combination of Cisplatin and Pemetrexed is one of several chemotherapy options that have proven successful enough to handle patients with malignant pleural mesothelioma / malignant pleural mesothelioma (MPM), but this combination can be very toxic to the body. There is no cure and treatments for malignant mesothelioma cancer without undesirable side effects.

In the journal the researchers noted that "there are two phases of a randomized study in Phase III shows the benefits for the prognosis of mesothelioma with the use of antifolates such as raltitrexed or pemetrexed, when combined with cisplatin. The study has shown an absolute improvement in overall survival an average of 2.6 and 2.8 months, compared with single treatment for cisplatin. This makes a lot of institutions using cisplatin and pemetrexed as the standard palliative chemotherapy treatment for malignant pleural mesothelioma. "

Unfortunately, the combination of cisplatin and pemetrexed produces unwanted toxic effects and it encourages researchers to study other chemotherapy drugs to be combined with pemetrexed. Researchers said, "Recently, two phase II trials have evaluated the efficacy of Carboplatin and pemetrexed in MPM. Both studies showed overall response rate of 18.6 and 25%, with a survival rate of 12.7 and an average of 14 months. Following on from these results, we have undertaken a retrospective analysis in patients with MPM treated with Carboplatin and Pemetrexed in our institution. "

In an effort to find a combination chemotherapy of mesothelioma with minimal toxicity and side effects, the researchers investigated further by replacing Cisplatin with Carboplatin when paired with Pemetrexed. Using a retrospective approach, researchers evaluated 49 cases of malignant pleural mesothelioma who were given a combination of Carboplatin and Pemetrexed and compare the results with data of cisplatin combination chemotherapy with Pemetrexed.

Level of disease control (known in the absence of progressive signs of mesothelioma over CT scan) for patients was 69 percent, and the percentage of partial response and stable disease by 28 percent and 41 percent. Clinical improvement is shown in figure 69 percent, the majority of patients reported an increase in profits after two cycles of chemotherapy. Toxicity is generally low and better than the toxicity of cisplatin with pemetrexed.

The average time to treatment failure was 4.6 months. The average overall survival in this study is 14 months, compared with the cisplatin-pemetrexed for 12.1 months. The authors suggested, "In conclusion, our data show a combination of Carboplatin and Pemetrexed may be an option in the treatment of mesothelioma, particularly in patients who experience problems with the use of cisplatin."

Xtreme Fat Loss Diet System!

Effectiveness of chemotherapy and its effects

Chemotherapy is a cancer treatment in the medical use of drugs to treat various types of cancer. Ordinary given before or after surgery. The goal of chemotherapy is to eradicate all the cancer cells get to the roots, up to a location that is not affordable scalpel and least able to control the cancer cells so as not to spread more widely.

Two main reasons Chemotherapy is often done to control or eliminate the tumor to relieve cancer symptoms such as pain. This type of chemotherapy is called palliative chemotherapy.

While chemotherapy does any other purpose is to prevent the reappearance of cancer cells after surgery or radiation therapy to control tumor.

This type of chemotherapy is called adjuvant chemotherapy. The way the chemotherapy is working with the target and eliminate cancer cells that grow very rapidly in the body.

Basically, the treatment of cancer depends on the type or types of cancer and where the cancer. Age, general health condition of patients and treatment system also affects the process of cancer treatment. In the case of cancer, the main treatment is through:

    Surgery or Surgery
    Chemotherapy or by giving drugs
    Beam radiotherapy or Use of Radiation

But in fact, will typically use more than one way of treatment. For instance surgery followed by chemotherapy or radiotherapy, and sometimes treatment must be done by using the 3 combination.

Basically the main goal of surgery is to remove the cancer as a whole because the cancer can be cured only if it has not spread to other places. While chemotherapy and radiation intended to kill cancer cells or stop the growth of cancer cells that are still left behind.

Chemotherapy is a treatment process by using medications aimed at killing or slowing the growth of cancer cells. Chemotherapy drugs are usually administered intravenously or orally. The frequency and duration of chemotherapy depends on the type of cancer, stage, other health problems, types of chemotherapy drugs are prescribed, and other methods of treatment used.

Are There Side Effects of Chemotherapy?
Depending on the type, chemotherapy is given every day, once a week, three weeks, even once a month. How many series of patients have to undergo chemotherapy, also depending on the type of cancer sufferers. The most feared side effects of chemotherapy is. Side effects of chemotherapy depend on many things, among other types of chemotherapy drugs, the condition of your body, your mental condition, and so on.

Chemotherapy side effects occur because chemotherapy drugs are very powerful, and kill not only cancer cells, but also attack healthy cells, especially cells that divide rapidly. Therefore the side effects of chemotherapy appear on parts of the body that his cells are rapidly dividing. Side effects can arise when doing the treatment or some time after treatment. Side effects that may arise is, among others:

    The body felt weak
    This is a common side effect is found, the onset can be sudden or slow. Sometimes it can continue until the end of treatment, and does not disappear simply by resting.
    Nausea and vomiting
    There are several chemotherapy drugs are more make nausea and vomiting. In addition there are some people who are very prone to nausea and vomiting. This can be prevented by a given anti-nausea drugs before, during, or after chemotherapy treatment.
    Indigestion
    Some types of chemotherapy drugs have an effect diarrhea. There's even a diarrhea accompanied by severe dehydration should be treated. Constipation can sometimes occur. If diarrhea: subtract fiber foods, cereals, fruits and vegetables. Drink plenty to replace lost fluids.
    Sprue and affect sense of taste
    Some chemotherapy drugs cause mouth diseases such as thick or infection. Chemotherapy can also damage taste receptors in the mouth. Changes in sense of taste is usually started a week after the chemotherapy began and lasted for 3-4 weeks.
    Hair loss
    Hair loss is temporary, usually two or three weeks after chemotherapy begins. Can also cause hair breakage near the scalp. Can occur after several weeks of therapy. Hair can grow back after chemotherapy is completed.
    Muscle and nerve disorders
    Some chemotherapy drugs cause tingling and numbness in the fingers or toes, and weakness in leg muscles.
    Effects on blood
    Some types of chemotherapy drugs can affect the bone marrow of work which is the manufacturer of the blood cells, thereby decreasing the number of blood cells. The most frequent is a decrease in white blood cells (leukocytes). Decrease in blood cells occur in every chemotherapy and blood tests will be carried out before the next chemotherapy to ensure blood cell count has returned to normal. Decrease in the number of blood cells can lead to infections, bleeding, and anemia.
    The skin can become dry and discolored
    More sensitive to the sun. Nails grow more slowly and there are white lines across.
    Hormone production is not stable
    Lowered libido and affect fertility in both men and women.

Some dietary supplement products claim to reduce the side effects of chemotherapy as well as rebuild the condition of your body. You can use it, but please check with an expert, and certainly with your doctor as well.

Adopted from www.deherba.com

Xtreme Fat Loss Diet System!

Pancreatic cancer therapy with paclitaxel

Pancreatic cancer, including cancers that are difficult to treat. It is seen from at least the development of effective chemotherapeutic drugs for cancers. Gemcitabine is the standard therapy and has been recommended. The problem is, after progression with gemcitabine achieved, not many treatment options is recommended, even NCCN recommends to get therapy clinical trials are being conducted. In addition, the choice of second-line therapy, ie capecitabine, 5-fluorouracil/leucovorin/oxaliplatin, or a combination regimen of capecitabine / oxaliplatin.

A retrospective study conducted recently on 30 the subject of people with pancreatic cancer in order to assess the benefits and tolerability of weekly cycles of paclitaxel as second-line therapy for patients with pancreatic cancer refractory to gemcitabine. Paclitaxel administered in doses of 80 mg/m2 per week (for 3

Preklinis Study: Folate Acid Supplementation Effects on Colorectal Cancer Risk

Xtreme Fat Loss Diet System!

In North America, the trend of folic acid exposure during fetal and early infant life showed significant improvement with respect to fortifikasi folic acid, the widespread use of folic acid as a supplement, and an increase in folic acid supplementation around the time of conception. The researchers from the University of Toronto, Canada, led by dr. Sie, to see whether folic acid supplementation associated with decreased colorectal cancer risk. For that, they did a study preklinis, the results published in the journal Gut in 2011.

In the study, a number of female rats are grouped into two categories: control diet group and diet group suplemental (2.5 x control). Diet provided by mating, during pregnancy and during breastfeeding. At the time

Multidetector Computed Tomography (MDCT) is recommended to Do Before Action Apendektomi

Xtreme Fat Loss Diet System!
Multidetector computed tomography (MDCT) is a sensitive and specific tool and should become standard treatment for the diagnosis of suspected appendicitis in adults, according to an analysis of the use of MDCT studies reported in the Annals of Internal Medicine in June 2011.
 In the study, conducted assessments manfaatdiagnostik MDCT for the diagnosis of suspected acute appendicitis in adults. From studies conducted retrospektf U.S. academic medical centers, found as many as 2871 consecutive adults referred for MDCT performed with suspicion of appendicitis from January 2000 until December 2009. Radiologist who was informed of indications interpreted not focus with

Drug Politerapi Antiepileptik During Pregnancy and Risk of Fetal Malformations

Xtreme Fat Loss Diet System!
During pregnancy, drug politerapi antiepileptik (OAE), which includes valproate sustained a risk of malformations in the fetus than politerapi without this drug. This finding is the result of the study dr. Lewis Holmes and colleagues, from MassGeneral Hospital for Children in Boston, which was published online in mid June 2011 in the Archives of Neurology. During this time, it is known that women who consume more than one type of OAE during pregnancy have a higher risk of having infants with severe congenital malformations, compared to pregnant women who use only one type of OAE. Studies conducted dr. Holmes and his team will further strengthen the evidence of close links politerapi OAE use by pregnant women with the risk of malformations in the fetus. The study, named the North American AED Registry revealed that the risk of malformations increased significantly in

Benefits and Risks Intra-arterial Chemotherapy for Retinoblastoma

Intra-arterial chemotherapy for the treatment of retinoblastoma can result in "dramatic response", but also raises the risk of side effects ranging from mild to severe. This finding revealed by dr. Carol Shields and colleagues, from the Wills Eye Institute Philadelphia, published in the Archives of Ophthalmology. In the study, intra-arterial chemotherapy (intra-arterial chemotherapy, IAC) was done in 17 children with retinoblastoma are aged 4 to 74 months. Complete response was found in 14 children and 10 of whom remained free of tumor when performed follow-up a year later.
Successful catheterization in 16 children with retinoblastoma median basal dimension of 20 mm and the average thickness of 9 mm. IAC is actually scheduled for 3 times with an interval of one month, but the researchers decided not to increase the cycles of chemotherapy if the tumor has shown complete regression. IAC is a primary therapy in 12 children, and the eyeball was saved in eight children among them - including all children who are classified as category C or D according to the International Classification of Retinoblastoma (scale categories: A through E; E most severe). Meanwhile, the eyeball is also saved on 2 of 4 children who underwent the IAC as a secondary therapy. Primary tumor regresses post-chemotherapy; basal dimensions shrink 31% and the thickness decreased 56%.
Tumor recurrence occurred in three children only once, each in the form of solid tumor, the seeds of the tumor in subretina (subretinal seeds), and the seeds of the tumor in the anterior chamber or glass body (anterior chamber or vitreous seeds). Enucleation had to be done in six children, external beam radiotherapy twice, and plaque radiotherapy once. Recognized researchers, IAC has a number of advantages over other therapeutic modalities for retinoblastoma cases, partly because the dose is small enough to do one day so enlarge the biological effects at the target location while minimizing toxic effects on other body parts. However, the IAC procedure is technically quite difficult, and children should be watched closely in order to be aware of the possibility of serious side effects. During follow-up period, reported some mild side effects of short duration, covering palpebra edema (in 13 children a month later), blefaroptosis (10 children), and orbital congestion (12 children), all of which recovered within 6 months. More serious side effects of oftalmika artery stenosis (3 cases of permanent, temporary 1 case) and central retinal artery occlusion (two cases of permanent, one temporary).
Researchers recommend that each health care center is working on fluorescein angiography IAC always do first in order to assess ocular blood flow, especially for detecting atrophy of the choroid. The team of researchers themselves have diagnosed five cases of choroid atrophy among patients who participated in this study. "The impact of atrophy of the choroid to the sharpness of vision can be very bad boy. In fact, enucleation should be performed on the eyeball atrophy choroid; if not, the child continues to be blind," said dr. Shields. Not encountered in cases of arterial embolism, metastasis, neurological defects, occlusion of the internal carotid artery or femoral artery, and stroke in children.
Thus, dr. Shields concludes that although retinoblastoma is very responsive to the IAC, the tendency should be wary of the emergence of toxic effects due to exposure to chemotherapy or radiotherapy. Therefore, the IAC for retinoblastoma should be considered with caution in certain cases.